Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp (QIPT) provides essential respiratory care equipment and home medical solutions through its nationwide network. This news hub offers investors and healthcare professionals timely updates on the company's operational developments in the home healthcare sector.
Access official press releases and verified news covering regulatory milestones, equipment approvals, and strategic partnerships. Our curated collection simplifies tracking QIPT's progress in key service areas including clinical respiratory equipment deployments, sleep therapy innovations, and oxygen therapy solutions.
Discover updates on Medicare compliance changes affecting medical rentals, new product certifications, and expansion of home ventilation services. This resource serves as your central reference for monitoring QIPT's position in the competitive medical equipment market.
Bookmark this page for streamlined access to operational updates, leadership announcements, and service area expansions. Check regularly for verified information about QIPT's initiatives in respiratory care technology and patient support programs.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider specializing in end-to-end respiratory care, has scheduled the announcement of its fiscal fourth quarter and full year 2024 financial results for December 16, 2024, after market close. The company will host a conference call for investors on December 17, 2024, at 10:00 a.m. ET, led by CEO Gregory Crawford and CFO Hardik Mehta. The call will be accessible via toll-free numbers for Canada/US participants and international callers, with a live webcast available through the company's investor relations website.
Quipt Home Medical Corp. (NASDAQ: QIPT; TSX: QIPT) reported its Q3 fiscal 2024 financial results. Key highlights include:
- Revenue increased 6.1% year-over-year to $64.0 million
- Organic growth contributed 3% year-over-year
- Adjusted EBITDA rose 2.7% to $14.2 million, representing 22.3% of revenues
- Net loss was $(1.7) million, or $(0.04) per diluted share
- Cash flow from operations for the nine months ended June 30, 2024, was $28.6 million
- The company served 270,087 unique patients in the nine months ended June 30, 2024, a 12.9% increase
Quipt faced challenges including the expiration of the Medicare 75/25 blended rate and the impact of the Change Healthcare cyber-attack. Despite these, the company maintains a strong balance sheet with a Net Debt to Adjusted EBITDA Leverage Ratio of 1.5x.
Quipt Home Medical Corp. (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider specializing in end-to-end respiratory care, has announced it will release its fiscal third quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call for investors on August 15, 2024, at 10:00 a.m. ET.
CEO Gregory Crawford and CFO Hardik Mehta will lead the call. Participants can join using the following numbers: Canada/US Toll Free: 1 (844) 763 8274, International: 1 (647) 484 8814. A live webcast will also be available on the company's investor relations website.
Quipt Home Medical (NASDAQ: QIPT; TSX: QIPT) announced its Q2 fiscal 2024 results, reporting a 10% increase in revenue to $64.0 million and a 14% increase in adjusted EBITDA to $14.9 million. Despite the expiration of the Medicare 75/25 blended rate and withdrawal of some Medicare Advantage members, the company maintained a strong adjusted EBITDA margin of 23.3%. Net income was a loss of $1.4 million, or $0.03 per diluted share. Cash flow from operations grew to $17.1 million for the six months ended March 31, 2024. Operational highlights include an 8% increase in unique patients served and a 6% increase in unique set-ups/deliveries. The company also announced a Normal Course Issuer Bid (NCIB) for share repurchases worth up to $5.0 million. Management highlighted resilience amid industry challenges and a strong balance sheet with $32.9 million in liquidity.
Quipt Home Medical Corp. (QIPT) announced the filing of its final base shelf prospectus, allowing the company to offer up to C$300,000,000 of common shares, preferred shares, debt securities, warrants, subscription receipts, and units over a 25-month period. The prospectus aims to provide access to new capital and securities for strategic acquisitions as needed.
Quipt Home Medical Corp. will release its fiscal second-quarter 2024 financial results on May 15, 2024. The Company, a U.S.-based home medical equipment provider specializing in respiratory care, will host a conference call the following day. The call-in details are provided for investors, and a webcast link will be available on the company's website.
Quipt Home Medical Corp., a U.S.-based home medical equipment provider, has announced a normal course issuer bid (NCIB) to repurchase up to 3,626,845 common shares, representing about 10% of its public float. The NCIB will start on May 6, 2024, and end by April 30, 2025, or when the maximum shares are repurchased. The company believes its shares are undervalued and sees this as an opportunity to enhance shareholder value.
FAQ
What is the current stock price of Quipt Home Medical (QIPT)?
What is the market cap of Quipt Home Medical (QIPT)?
